Paragon Capital Invests $1.19M in BioMarin Pharmaceutical

Institutional investor adds 20,040 shares of biotech firm to portfolio

Apr. 13, 2026 at 10:52am

Got story updates? Submit your updates here. ›

An extreme close-up of intricately engineered metal gears and machinery, conveying the complex financial infrastructure supporting the biotech industry's innovative drug development.A major institutional investment in a leading biotech firm signals confidence in the specialized pharmaceutical sector's growth potential.Novato Today

Paragon Capital Management Inc. purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the fourth quarter, acquiring 20,040 shares of the biotechnology company's stock valued at approximately $1,191,000, according to a disclosure filed with the Securities & Exchange Commission.

Why it matters

The investment by Paragon Capital, a prominent institutional investor, in BioMarin Pharmaceutical reflects confidence in the biotech firm's growth potential. BioMarin develops therapies for rare genetic and metabolic diseases, an area of increasing focus and investment in the pharmaceutical industry.

The details

In addition to Paragon's new position, other major institutional investors and hedge funds have also modified their holdings in BioMarin Pharmaceutical recently. Federated Hermes Inc. increased its stake by 292.6% last quarter, while Mediolanum International Funds Ltd and Rice Hall James & Associates LLC also added significantly to their positions in the company.

  • Paragon Capital Management Inc. purchased the new position in BioMarin Pharmaceutical during the fourth quarter of 2025.
  • The disclosure of the investment was filed with the SEC on April 13, 2026.

The players

Paragon Capital Management Inc.

An institutional investment firm that has purchased a new position in BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

A biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases.

Got photos? Submit your photos here. ›

The takeaway

Paragon Capital's investment in BioMarin Pharmaceutical reflects the growing interest and confidence in the biotech sector, particularly companies focused on rare disease treatments. As the pharmaceutical industry continues to evolve, strategic investments by major institutional players will shape the landscape of innovative drug development.